The PAI-1 gene promoter 4G/5G polymorphism was found to be associated with plasma PAI-1 activity in white but not yet in Chinese patients. Hypertension might exaggerate the 4G/5G genotype effect on plasma PAI-1. Methods: The 4G/5G genotypes and plasma PAI-1 levels were determined in 565 Chinese, 211 with and 354 without hypertension to study the genotype effect and the mode of gene-environment interaction. Results: Hypertensive patients showed significantly higher plasma PAI-1 activity (18.2 Ϯ 10.0 v 14.6 Ϯ 8.8 IU/mL, P Ͻ .001) than normotensive subjects, and also higher body mass index (BMI) and plasma triglyceride (TG), but had neither significant difference in the 4G allele frequency (0.531 v 0.549) nor in the 4G/4G genotype percentage (24.6% v 26.5%). The 4G/4G genotypic group had higher plasma PAI-1 activity (17.6 Ϯ 10.2 v 14.5 Ϯ 7.3 IU/mL, P ϭ .027) than the 5G/5G genotypic groups, but the statistic significance was present in women (18.1 Ϯ 10.0 v 14.8 Ϯ 6.9 IU/mL, P ϭ .025) and not in men (17.2 Ϯ 10.5 v 14.3 Ϯ 7.7 IU/mL, P ϭ .39) after log transformation. Multiple regression analysis of all cases documented the independent effect of BMI (P ϭ .000), plasma TG (P ϭ .000), age (P ϭ .006), gender (P ϭ .046), and the PAI-1 genotype (4G/4G v 5G/5G, P ϭ .012) on plasma PAI-1 activity. However, the significant association of 4G/4G genotypes with higher plasma PAI-1 activity was present in women (P ϭ .004) but not in men. There was a significant difference (P ϭ .04) on the plasma TG-PAI-1 activity correlations between the 4G/4G (r ϭ 0.521) and 5G/5G (r ϭ 0.117) genotypic groups of hypertensive patients.
I
ncreased plasma plasminogen activator inhibitor-1 (PAI-1) activity with suppressed fibrinolysis was associated with first and recurrent myocardial infarction (MI) among young patients 1, 2 and with ischemic events among atherosclerotic patients. 3 Hypofibrinolysis may precipitate arterial occlusion by contributing a prothrombotic state involved in the maintenance of thrombi, 4 and can accelerate the atherosclerotic process by allowing fibrin deposition and thrombosis within developing plaque lesions. 5, 6 Circulating PAI-1 activity was elevated in patients with hypertension 7, 8 or type 2 diabetes, 9, 10 and this may represent one of the mechanisms for high risk of coronary artery disease (CAD) or MI in these patients. The metabolic feature that has been linked to elevated PAI-1 is insulin resistance syndrome [7] [8] [9] [10] [11] [12] with clustering of hyperinsulinemia, dyslipidemia, glucose intolerance, obesity, and hypertension.
A common guanosine deletion/insertion (4G/5G) polymorphism has been identified within the PAI-1 gene promoter at 675 bp upstream from the transcription site. 13 In vitro studies have indicated that the 5G allele, but not the 4G allele, contains an additional binding site for a tran-scriptional repressor. 14 In vivo, plasma PAI-1 activity has been related to the 4G/5G polymorphism with the 4G allele carrying higher PAI-1 level in white patients with MI 15 or type 2 diabetes 16, 17 and without clinical evidence of atherosclerosis, 18 and in Japanese patients with acute coronary syndrome. 19 Furthermore, a different correlation of plasma PAI-1 activity on triglyceride (TG) level among the 4G/5G genotypes was shown in diabetic 16, 17 and dyslipidemic 21 white patients. On the other hand, lack of association between the 4G/5G genotype, PAI-1, and TG level was also reported in a healthy population of white French, 21, 22 Japanese healthy men, 23 and Pima Indian diabetic and non diabetic patients. 24 In particular, Henry et al 22 has showed that metabolic factors are much more important than genetic polymorphism in determining plasma PAI-1 levels when the family data were accessed.
To date no published data are available concerning the 4G/5G genotype effect on plasma PAI-1 activity in the Chinese population. In addition, the impact of 4G/5G polymorphism on the relationship between plasma PAI-1 and TG levels in hypertensive patients is not clearly understood. Our previous studies 8, 25 had shown correlations of plasma PAI-1 to insulin sensitivity, dyslipidemia, blood pressure (BP), and glucose tolerance but not to angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism in Chinese patients with hypertension. Hypertensive patients carrying the 4G/4G genotype may be at greater risk for CAD or MI because of higher plasma PAI-1 levels, which are modulated by plasma TG. To test this hypothesis, we examined the distribution of 4G/5G polymorphism in Chinese patients with and without hypertension and studied the 4G/5G genotype effect on plasma PAI-1 levels and its impact on the plasma TG-PAI-1 correlation.
Patients and Methods
The population included in this study were 565 unrelated Chinese subjects, 211 with and 354 without hypertension. They were recruited from the cardiology clinic and health examination center of the Tri-Service General Hospital, Taipei, Taiwan. Hypertension was diagnosed as either systolic BP Ͼ160 mm Hg or diastolic BP Ͼ95 mm Hg on at least three separate occasions. Hypertriglyceridemia was defined as plasma TG Ͼ160 mg/dL. Diabetes was diagnosed if the fasting plasma glucose higher than 126 mg/dL on two separate occasions. The patients volunteered to join this study following a protocol approved by the National Defense Medical Center Human Subjects Committee. Physical examination, review of medical history, and routine biochemistry were performed on each subject before entrance into this study. None of the study subjects had a history or clinical evidence of stroke, acute MI, heart failure, or renal insufficiency. There was no apparent cause of secondary hypertension on clinical ground in all patients.
Blood was drawn at about 9 AM after a 15-min rest and an overnight fast to reduce interference by the diurnal variation 26 of PAI-1. The samples were collected in tubes containing sodium citrate, plasma separated within 1 h by centrifugation for 20 min at 3000 g and stored at Ϫ70°C until assayed. Plasma glucose, total cholesterol, and TG were determined with commercially available kits as described previously. 8 Plasma PAI-1 antigen was quantified with enzyme-linked immunosorbent assays. 27, 28 Plasma PAI-1 activity was determined with a two-stage, indirect enzymatic assay based on the addition of excess tPA (40 IU/mL) to the samples and measurement of the residual tPA activity. 29 One unit of PAI-1 activity was defined as the amount of PAI-1 that inhibits 1 IU of international tPA standard. The reagent kits for assay of PAI-1 antigens and activities were purchased from Biopool AB, Umeȧ, Sweden.
Genomic DNA was extracted from 100-L buffy coat using an IsoQuick Nucleic Acid Extraction Kit (MicroProbe, Bothell, WA). The 4G/5G genotypes of PAI-1 gene promoter were determined for each subject by polymerase chain reaction (PCR) amplification and single-strand conformation polymorphism (SSCP) analysis with some modification of the procedure described by Ridker et al. 30 Briefly, the 5Ј and 3Ј primers used in PCR were TAA-CCC-CTG-GTC-CCG-TTC and CAG-AGG-ACT-CTT-GGT-CTT-TCC, respectively. The target sequence around the 4G/5G polymorphism was amplified in a 50-L reaction with a Perkin-Elmer/Applied DNA thermal cycler 2400 (Perkin-Elmer Corporation-Applied Biosystems, Foster City, CA). Six microliters of denatured PCR product was applied into and separated on a GeneGel Excel 12.5/24 with the GenePhor electrophoresis unit and gels were stained with DNA silver staining kit (Amersham Pharmacia Biotech, Uppsala, Sweden). Three patterns were apparent on the stained gel and the representative PCR products sequenced to identify the 4G/4G, 4G/5G, and 5G/5G genotypes.
All group data are reported as means Ϯ SD. Plasma levels of PAI-1 activity, antigen, and TG were log transformed to remove positive skewness. The statistic significance of differences on mean levels of variables among the three genotypes was examined by analysis of variance (ANOVA). Multiple linear regression was used to evaluate the association of plasma PAI-1 levels with PAI-1 genotypes (4G/4G v 5G/5G and 4G/4G v 4G/5G) while controlling for all potential confounding factors. Pearson correlation coefficients were calculated between plasma PAI-1 and TG levels after log transformation in each genotypic group. Fisher's z test was used to examine the difference in correlation parameters between genotypes. The statistic significance of differences was assumed to be present at P Ͻ .05.
Results
The characteristics of 565 Chinese subjects with and without hypertension, hypertriglyceridemia, or diabetes are shown in Table 1 . It can be noted that patients with hypertension, hypertriglyceridemia, or diabetes had significantly higher plasma levels of PAI-1 antigen and activity but did not show greater 4G/4G genotype percentage and 4G allele frequency than those without these disorders. In addition, hypertensive patients had higher body mass index (BMI) and plasma TG than subjects with normal BP. Hypertriglyceridemic patients showed higher age, BMI, systolic and diastolic BP, fasting plasma glucose, and total cholesterol than subjects with normal TG. Diabetic patients had higher age, BMI, and TG than nondiabetics. It indicated that the fibrinolytic function was impaired in patients with hypertension, hypertriglyceridemia, or diabetes.
There was no significant difference in age, gender, BMI, systolic and diastolic BP, fasting plasma glucose, total cholesterol, TG, and PAI-1 antigen among the three PAI-1 genotypic groups of 565 Chinese subjects. However, the 4G/4G genotypic group was found to have higher mean values of plasma PAI-1 activity (17.6 Ϯ 10.4 v 15.6 Ϯ 9.5 and 14.5 Ϯ 7.3 IU/mL, P ϭ .027) than those with the 4G/5G and 5G/5G genotype, but the significance became modest (P ϭ .062) after log transformation. Table 2 summarized the characteristics of 305 men and 260 women grouped by PAI-1 promoter 4G/5G genotypes. It can be seen that both men and women have higher plasma PAI-1 activity (17.2 Ϯ 10.5 v 14.3 Ϯ 7.8 and 18.1 Ϯ 10.0 v 14.8 Ϯ 6.9 1U/mL, respectively) and antigen (31.3 Ϯ 20.8 v 28.6 Ϯ 15.9 and 32.4 Ϯ 17.9 v 28.5 Ϯ 17.6 ng/mL, respectively) levels in the 4G/4G genotypic groups than those in the 5G/5G genotypic groups. However, the statistical significances were present only in women (P ϭ .025 and P ϭ .027, respectively) and not in men after log transformtion.
Multiple linear regression analysis of 565 Chinese subjects showed that the PAI genotype (4G/4G v 5G/5G, P ϭ .012) was a significant predictor for plasma PAI-1 activity after adjustment for age (P ϭ .006), gender (P ϭ .046), BMI (P ϭ .000), systolic BP (P ϭ .40) and diastolic BP (P ϭ .80), fasting plasma glucose (P ϭ .39), total cholesterol (P ϭ .54), and TG (P ϭ .000). The significant determinants of plasma PAI-1 antigen, however, were BMI (P ϭ .000), TG (P ϭ .000), and fasting plasma glucose (P ϭ .019) only. Furthermore, multiple linear regression analysis of 305 men and 260 women is shown in Table 3 . In women the PAI genotype (4G/4G v 5G/5G) was a significant predictor both for plasma PAI-1 activity (P ϭ .004) and antigen (P ϭ .013) after adjustment for all potential confounders. However, the significant associations of 4G/4G genotype with higher plasma PAI-1 activity and antigen could not be seen in men. Table 4 showed the Pearson correlation coefficients of on plasma TG-PAI-1 levels by PAI-1 genotypes in hypertensive patients and normotensive subjects. Among hypertensive patients, the correlation of plasma PAI-1 activity with TG level was significant in the 4G/4G (r ϭ 0.521, P ϭ .000) and 4G/5G (r ϭ 0.361, P ϭ .000) genotypes but not in the 5G/5G genotype (r ϭ 0.117, P ϭ .524). There was a significant difference (P ϭ .04) on the plasma TG-PAI-1 activity correlations between the 4G/4G and 5G/5G genotypic groups of hypertensive patients. A similar genotype association was found in the Pearson correlation coefficients of plasma TG on PAI-1 antigen in hypertensive patients (4G/4G, r ϭ 0.496, P ϭ .001; 4G/ 5G, r ϭ 0.246, P ϭ .009; 5G/5, r ϭ 0.241, P ϭ .185). Conversely, in normotensive subjects, there was no significant relationship of 4G/5G genotypes with the correlation between plasma TG and PAI-1 activity or antigen.
Discussion
The findings of the present study extended the positive association between the 4G/5G PAI-1 genotype and plasma PAI-1 activity, previously described in whites [15] [16] [17] [18] in comparison to a Chinese population, with and without hypertension. The contribution of PAI-1 genotypes to plasma PAI-1 levels appeared greater in women. This gender difference was similar to that reported by Henry et al 22 with white family data. Furthermore, patients with hypertension were found to have impaired fibrinolysis due to elevated plasma PAI-1 and showed a 4G/5G genotypedependent interaction of plasma TG and PAI-1 activity. The hypothesis I tested was that hypertensive patients with 4G/4G genotype might present higher plasma PAI-1 activity, modulated by plasma TG, and thus had lower fibrinolytic function, predisposing to a greater risk for CAD or MI. The results from the present study support this point of view in that a gene-environmental interaction may contribute to the high risk of atherothrombotic disease in patients with hypertension, especially in women.
A modulation by the 4G/5G genotype of the interaction between plasma TG and PAI-1 has been previously reported in diabetic 16, 17 and dyslipidemic 20 populations. In either diabetic or dyslipidemic patients carrying the 4G/4G genotype but not the 5G/5G genotype, higher TG levels are associated with higher PAI-1 levels. The present study data extended such a gene-environment interaction to the population with hypertension. In hypertensive patients carrying the 4G/4G genotype but not the 5G/5G genotype, a significant correlation between plasma TG and PAI-1 activity was observed. It suggested the existence of a common mechanism for PAI-1 modulation and geneenvironment interaction in patients with diabetes, dyslipidemia, and hypertension, which are related to the insulin-resistant syndrome. Plasma PAI-1 levels were higher in patients with hypertension, dyslipidemia, or diabetes and the 4G/4G genotype could predispose these patients to atherothrombotic disease due to the TG-modulated elevation of plasma PAI-1 activity.
The 4G/4G genotype has been identified by Mansfield et al 31 as an independent risk factor for CAD in patients with type 2 diabetes. Gardemann et al 32 extended this positive finding to patients with hypertension or obesity in a large population study. It was estimated that the odds ratios of 4G/4G genotype for CAD were 1.45 in patients with hypertension, 1.59 in obese subjects, and 2.0 in obese hypertensives. In a meta-analysis, Iacoviello et al 33 concluded that the 4G allele confers a slight increase in risk of MI and the risk of MI for carriers of the 4G allele in populations at higher risk of MI is almost twice that of low-risk populations. These reports suggested that the 4G/4G genotype may predispose to elevated plasma PAI-1 and hypofibrinolysis, and perhaps requiring interactions with other genetic or environmental factors, especially the insulin resistant syndrome such as obesity, hypertension, dyslipidemia, and diabetes, to increase the risk for CAD or MI. My data of interactions among the 4G/5G genotype, plasma PAI-1, and TG levels in patients with hypertension may provide part of the evidence supporting such an explanation.
In conclusion, the present study showed an association between the PAI-1 gene promoter 4G/5G polymorphism and plasma PAI-1 activity in Chinese patients with and without hypertension, especially in women. A similar distribution of the 4G/5G genotypes in hypertensives and normotensives indicated that this gene variant by itself is Abbreviations as in Tables 1-3 . The values of plasma PAI-1 activity and antigen and triglyceride were log transformed. * P Ͻ .05 by Fisher's z test for comparing two correlation coefficients between 5G/5G and 4G/4G genotypes.
not associated with hypertension. Furthermore, patients with hypertension had higher plasma PAI-1 levels than normotensive subjects and those hypertensives with the 4G/4G genotype showed greater effect of plasma TG on PAI-1 activity. The results suggest that possession of the 4G/4G genotype in patients with hypertension exaggerates the hypofibrinolysis in the presence of hypertriglyceridemia and may predispose to atherosclerosis and a thrombotic event. However, the conclusions are limited to Chinese subjects recruited at specialized departments of a hospital. It is not clear whether the restriction to this patient group introduced a selection bias and the findings may or may not reflect the situation in the overall population. A further large population-based case-control study is needed to address some of the unresolved questions evolving from the present data.
